Researchers evaluate molecular imaging in detecting breast cancer | Migraine symptoms may be eased using brain wave therapy | Rolapitant may help reduce chemo side effects in GI cancers
September 21, 2016
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
Top Story
Researchers evaluate molecular imaging in detecting breast cancer
Mayo Clinic researchers say molecular breast imaging, combined with mammograms, yields a nearly fourfold higher likelihood of detecting breast cancer in women with dense breasts, compared with mammography alone. A study in a radiology journal involving 1,696 women with dense breasts showed that MBI detected 13 cancer malignancies that weren't discovered by mammograms.
NBC News (9/14),  The Kansas City Star (Mo.)/McClatchy Washington Bureau (9/15) 
LinkedIn Twitter Facebook Google+ Email
Clinical News & Research
Migraine symptoms may be eased using brain wave therapy
Sound waves may help even out brain activity to ease migraine symptoms and lower blood pressure, according to data scheduled to be presented at the American Heart Association's Council on Hypertension 2016 Scientific Sessions. High-resolution, relational, resonance-based, electroencephalic mirroring, or HIRREM, senses imbalances in the brain via sensors placed on patients' scalps and sends the information to a computer, which then creates tones that are played back to the patient. (9/15) 
LinkedIn Twitter Facebook Google+ Email
Rolapitant may help reduce chemo side effects in GI cancers
Patients with gastrointestinal or colorectal cancer who get highly or moderately emetogenic chemotherapy may have less nausea and vomiting if they are given rolapitant with a 5-HT3 receptor antagonist and dexamethasone, according to study data presented at the 2016 Palliative Care in Oncology Symposium. Researchers said patients given rolapitant had higher rates of complete response compared with those taking a placebo.
Oncology Nurse Advisor online (9/15) 
LinkedIn Twitter Facebook Google+ Email
Industry Report
FDA approves modified dosing regimen for BMS' Opdivo
The modified dosage regimen for Bristol-Myers Squibb's Opdivo, or nivolumab, has been approved by the FDA for the treatment of advanced renal cell carcinoma, unresectable or metastatic melanoma and metastatic non-small cell lung cancer. The drug is now recommended as a 240-mg intravenous, flat-dosing regimen every two weeks until intolerable toxicity or disease progression. (9/16) 
LinkedIn Twitter Facebook Google+ Email
Glenmark and US company to develop, market generic cancer drug
India-based Glenmark Pharmaceuticals will work with US-based Particle Sciences to create a generic of breast- and lung-cancer drug Abraxane, by Celgene. Particle expects to file an abbreviated new drug application in fiscal year 2019.
The Economic Times (India)/Press Trust of India (9/19) 
LinkedIn Twitter Facebook Google+ Email
News from the Field
Study finds no tie between physician employment, better hospital care
A study in the Annals of Internal Medicine showed hospital employment of physicians increased from 29% in 2003 to 42% in 2012, but researchers did not find an association between the switch to an employment model and improvements in quality metrics, such as mortality and readmissions. The study found large hospitals, teaching facilities and nonprofits were more likely to move to physician employment.
Medscape (free registration) (9/19) 
LinkedIn Twitter Facebook Google+ Email
Health Policy
Federal government has little power to control drug prices
Allowing Medicare to negotiate prices directly with drugmakers would do little to reduce overall drug costs, and capping patients' out-of-pocket drug costs would probably lead to higher insurance premiums, according to this Kaiser Health News analysis.
Kaiser Health News (9/16) 
LinkedIn Twitter Facebook Google+ Email
Final rule on clinical trial results reporting released by HHS
A final rule has been issued by HHS requiring companies to post results of interventional studies involving FDA-approved and unapproved devices, drugs and biological products in the database effective Jan. 18, 2017. The rule, which has been extended by a final NIH policy to all trials funded by the institute regardless of phase, is not applicable to small feasibility studies of devices, Phase I trials of biological products and drugs, and data for investigational products under expanded access protocols.
BioCentury (9/16) 
LinkedIn Twitter Facebook Google+ Email
Advancing Health Care
Alzheimer's researchers need to collaborate, EMA official says
Expanded data sharing and collaboration would help the Alzheimer's disease research community learn from previous failures and allow new drug targets to be developed and validated, says Enrica Alteri, head of human medicines research and development support at the European Medicines Agency. She said the EMA and FDA are working together on guidelines and standards to streamline Alzheimer's disease drug development.
Regulatory Focus (9/19) 
LinkedIn Twitter Facebook Google+ Email
It's time to renew your SNMMI membership
SNMMI membership expires on Sept. 30, 2016. All SNMMI and SNMMI-TS members can now renew their membership online. Let SNMMI help you maintain professional credentials, keep you up-to-date on industry developments and advance your career with professional development opportunities. Renew your membership online today. We look forward to serving you for another year!
LinkedIn Twitter Facebook Google+ Email
Celebrate 30 years of Nuclear Medicine and Molecular Imaging Week!
Help celebrate the 30th anniversary of Nuclear Medicine and Molecular Imaging Week by showing your support for the profession. Read the official 1986 resolution, then grab your 2016 gear before it's all gone. Order today -- products are selling out!
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
An organization's ability to learn, and translate that learning into action rapidly, is the ultimate competitive business advantage.
Jack Welch,
corporate leader and author
LinkedIn Twitter Facebook Google+ Email
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information